Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.
Por:
Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F, Moreno S and CoRIS-Biobanco
Publicada:
1 ene 2015
Resumen:
Successful combined antiretroviral therapy (cART) does not always result in complete CD4 T-cell recovery despite the effective control of HIV replication. Because telomere dysregulation can lead to an abnormal cell proliferation, we hypothesized that the lack of CD4 recovery may be related to telomere defects; We thus evaluated the association between telomere length (TL) and CD4 T-cell recovery 48 weeks after cART initiation in virologically suppressed patients, and its possible relationship to oxidative stress (OS) and nitrosative stress (NOx) markers.
Filiaciones:
Blanco JR:
*Department of Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain
†Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain
‡Oncologia-CIBIR, Logroño, Spain
§Biología Experimental Universidad de Jaén, Jaén, Spain
Infectious Diseases. Hospital General del Elche and University Miguel Hernández, Alicante, Spain
¶Hospital de La Paz, Madrid, Spain
#Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
and **Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
|